Journal article
A prognostic score at diagnosis for Ewing tumor patients with metastatic disease at extrapulmonary sites
- Ladenstein, R. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Pötschger, U. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Le Deley, M. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Whelan, J. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Paulussen, M. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Oberlin, O. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- van der Berg, H. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Dirksen, U. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Craft, A. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
- Jürgens, H. St. Anna Children's Hospital, Vienna, Austria; Children's Cancer Reserach Institut, Vienna, Austria; Institut Gustave Roussy, Villejuif, France; Middlesex Hospital, Department of Oncology, London, United Kingdom; University Children's Hospital Basel, Basel, Switzerland; Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; University Children's Hospital, Münster, Germany; The Royal Victoria Infirmery, Newcastle upon Tyne, United Kingdom; University Children's Hospital, Münster, Germany
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2009, vol. 27, no. 15_suppl, p. 10544-10544
English
10544 Background: To assess prognostic factors at diagnosis in prospectively treated patients with primary extra-pulmonary metastatic Ewing tumors (EPM-ET) of the EURO-E.W.I.N.G. 99 Study. Methods: From 1999 to 2005, 281 patients were enrolled. Median age was 16.2 years (0.4–49). Primary site was extremity in 84 patients and axial in 197 (115 pelvic sites), with a tumor volume >200ml in 171 patients. Treatment consisted of 6 VIDE cycles, one VAI/VAC cycle, local treatment (surgery and/or radiotherapy), and high-dose busulfan-melphalan followed by peripheral stem cell transplantation (HDT/SCT). Results: After a median follow up of 3.8 years, event-free survival (EFS) and overall survival (OS) at 3 years for all 281 patients were 27%±3% and 34%±4%. Six VIDE cycles were completed by 250 patients (89%); 169 (60%) received HDT/SCT. Cox regression analyses demonstrated increased risk for patients with more than two bone metastatic sites (hazard ratio: HR 2.0), a primary tumor volume >200ml (HR 1.8), bone marrow metastases (HR 1.6), age >14 years (HR 1.6), and additional lung metastases (HR 1.5). A risk score based on these HR identified three risk groups with EFS rates of 50% for scores <_3 (82 patients), 25% for scores >3 to <5 (102 patients), and 10% for scores >_5 (70 patients), p< 0.0001. Conclusions: A proportion of EPM-ET patients may survive with intensive multimodal therapy. Age, tumor volume, and extent of metastatic spread are relevant risk factors. A score based on these factors identifies EPMD-ET patients with a more favorable outlook at diagnosis and may facilitate risk adapted treatment approaches. No significant financial relationships to disclose.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1200/jco.2009.27.15_suppl.10544
- ISSN 0732-183X
- Persistent URL
- https://sonar.ch/global/documents/231819
Statistics
Document views: 25
File downloads: